QNRX News and Press, Quoin Pharmaceuticals Ltd. From 03/02/23

ASHBURN, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its 2022 f...

Quoin Pharmaceuticals ( NASDAQ: QNRX ) priced its reasonable best efforts stock offering of 24.75B shares represented by 4.95M ADS at a purchase price of $1/ADS and pre-funded warrants to purchase 10.25B shares represented by 2.05M ADS at a per pre-funded warrant price of $0.9999...

ASHBURN, Va., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" pu...

Company’s Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing All Six Target Clinical Sites are on Track to be Fully Opened by Year End ASHBURN, Va., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Co...

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Conference Call November 10, 2022, 10:00 AM ET Company Participants Gordon Dunn - CFO Michael Myers - CEO Conference Call Participants Aydin Huseynov - Ladenburg Thalmann James Molloy - Alliance Glob...

Quoin Pharmaceuticals press release ( NASDAQ: QNRX ): Q3 Loss per ADS of -$0.94 beats by $0.41 . Ended Q3 with ~$15.2M in cash and marketable securities. Ongoing clinical study for QRX003 in Netherton Syndrome continues to progress, with a majority of clinical site...

Company completed a public offering for aggregate gross proceeds of $16.8 million Majority of clinical sites now open in clinical study to evaluate QRX003 for Netherton Syndrome Quoin announced plans to initiate second clinical trial to evaluate QRX003 in Netherton Syndr...

ASHBURN, Va., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today updated timing for its third quarter 2022...

ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its third quarter 2022 financial res...

Are These Penny Stocks To Buy Right Now Or Avoid Entirely? This article will discuss penny stocks to buy. Specifically, the “to buy” part is based on several Wall Street analysts. It’s also a continuation of our article 3 Penny Stocks With 1,000% Upside Potential ...